Member Info for Newuncle

I assume the epipens are single use devices so to meet demand production would have to be scaled up massively along with increasing labs capacity, partnership with one or more major players seems the obvious route to market to me?

Such a shame that the market is dominated by so many trading this for pennies every day when if they just held they could be trading them for £s......

Yes vater them rubbish bins won't empty themselves will they.....

Alex Schlich, Managing Director. ​ Alex has over 20 years experience in fund management, investment banking and strategy consulting.

Bamb

Thank you for posting that link it's a must read for all genuine holders here. Brilliant stuff. Again thank very much Bamb, exactly what a BB is for.

Oxford Biodynamics

Although I perhaps should be right in the frame as far as celebrating Oxford Biodynamics (OBD)’s prostate screening blood test, and its expedited arrival, given my demographic, it has been the share price rise that has really been a standout. What is interesting here is that almost a year ago there was a decent charting set up when the stock was in the upper teens. However, this time the stock gapped up on the news day, and stayed up. The set up was an island reversal, the stock having gapped in May / June. The reason the island reversal works so well is that the gap down to start the formation flushes out the weak hands. Then the gap higher catches out the bears. One would suspect that there were rather a lot of them better on the company getting their PSE test over the line. This would explain why the shares have effectively tripled since the news.

Vater maybe you should follow your own advice that you posted etc?

Credibility zero

See below

suppose all those arguments are a bit fruitless,as each individual point of view will be dependant on the point of entry . If you were buying few years ago at 30p- 50p or higher then, yes you might me bitter and disappointed. I entered in February at ridiculously low prices with 0.5m shares in my portfolio. 40% up so far, very little downside for me at the moment. Can it drop from those levels yes it can, can it go up further yes it can, can it go down all the way to 0, unlikely but possible. There is too many unknowns to predict the future. If you like the story, hold or buy. If you don't like the story , sell off and move on.

There's always a vater type poster on every share that's done big things, pointless debating with them as they will always prove their so called negative research. Engagement is totally pointless they won't stop whatever is said. Seen it so many times elsewhere

Some will always want to talk down a share, let em you can't educate pork as the saying goes. Either jealousy or wanting in cheaper . Using spurious irrelevant arguments to spook others

Eyes on the prize here guys

I see hasiba has watched the vox markets podcast and quoted word for work from them re being too highigh for them. Imo I am happy to ignore that.

The only end-to-end 3D genomics solution

Ready to use powerful EpiSwitch tools + a full-stack bioinformatic tool suite with low analytical overhead.

With the power of EpiSwitch Array Kit and EpiSwitch Portal, we are able to rapidly build and deploy powerful molecular tests to address the most challenging questions in precision medicine and clinical trial stratification.

I would add that OBD have their so called "flagship$ CIRT test for colorectal cancer too.

Idiot and a liar jeez

If idiot you accused me of trolling enet and you were buying it and calling it a strong buy calling me a Samaritan for my posts warming others. Get lost

You talking to me

The other one is still in development and not approved.

Krull yes more applications definitely available

Sam,

I might top slice some at £300 myself

Been away, what did I miss?

TT,

Totally agree with that, if (and they probably are) Directors and their advisers are in discussions with potential partners then that would be 100% subject to strict NDAs and confidentiality. Lots of legal eagles would be involved along with a raft of other experts and any contract discussions would vary from country to country etc etc and alot of other related stuff. Not a chance in hell directors would want to let anything slip out at this time.